ELDEPRYL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Eldepryl, and what generic alternatives are available?
Eldepryl is a drug marketed by Norvium Bioscience and is included in one NDA.
The generic ingredient in ELDEPRYL is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eldepryl
A generic version of ELDEPRYL was approved as selegiline hydrochloride by I3 PHARMS on April 1st, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ELDEPRYL?
- What are the global sales for ELDEPRYL?
- What is Average Wholesale Price for ELDEPRYL?
Summary for ELDEPRYL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 31 |
| Clinical Trials: | 2 |
| Patent Applications: | 4,730 |
| Drug Prices: | Drug price information for ELDEPRYL |
| DailyMed Link: | ELDEPRYL at DailyMed |
Recent Clinical Trials for ELDEPRYL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Second Affiliated Hospital of Soochow University | Phase 4 |
| University of South Florida | Phase 4 |
US Patents and Regulatory Information for ELDEPRYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | ELDEPRYL | selegiline hydrochloride | CAPSULE;ORAL | 020647-001 | May 15, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
